(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Christian Gratzke discussing the time course profile of adverse events with darolutamide in the ARAMIS phase 3 trial. Darolutamide is a structurally distinct and highly potent androgen-receptor inhibitor that improved metastasis-free survival by almost 2 years and reduced the risk of death by 31% versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial.1 Men with nmCRPC are generally asymptomatic and may receive prolonged treatment with androgen receptor inhibitors. Understanding the burden and time course of adverse events commonly associated with androgen receptor inhibitors that may impact patients’ daily life will help inform optimal treatment selection for men with nmCRPC.